Fellowship · Grand Rapids, MI
Sponsored by Corewell Health – Grand Rapids/Michigan State University · Director Renzo Loyaga-Rendon
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM.
Circulation · 2025 · 62 citations · David Fermin
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
JAMA cardiology · 2023 · 153 citations · David Fermin
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.
JACC. Heart failure · 2024 · 84 citations · David Fermin
Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial.
JACC. Cardiovascular imaging · 2025 · 41 citations · David Fermin
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial.
Circulation. Cardiovascular imaging · 2024 · 41 citations · David Fermin
Improved 2-year heart transplant survival with moderate hypothermic donor heart preservation in the GUARDIAN heart registry.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026 · 6 citations · Renzo Loyaga-Rendon
HFSA Expert Consensus Statement on the Medical Management of Patients on Durable Mechanical Circulatory Support.
Journal of cardiac failure · 2023 · 28 citations · Renzo Loyaga-Rendon
Aortic valve disorders and left ventricular assist devices.
Frontiers in cardiovascular medicine · 2023 · 24 citations · Renzo Loyaga-Rendon